Home Team & Track Record Our Newsletter Featured Companies  · Compass Pathways (CMPS)  · SpaceX (SPCX) AI-Assisted Portfolio Analysis Blog Contact Us Disclosure

Research Profiles

Featured Companies

Curated, compliance-reviewed stock profiles — each one thoroughly researched, vetted, and presented with full transparency so you can make informed decisions.

The Stock Sleuth — Wall Street Profit Search investigative research mascot

The Stock Sleuth

"Do the math..."
Current Recommendation

Compass Pathways Plc

NASDAQ: CMPS

Psychedelic Medicine · Clinical-Stage Biopharmaceuticals

The most advanced psychedelic-medicine company in the world — two successful Phase 3 trials, an active rolling NDA at the FDA, and a White House Executive Order accelerating the runway to commercial launch. We flagged CMPS at $9.30 in April 2026; it has since run to a high of $15.07, with Big Pharma's move into the space validating the thesis.

  • Two successful Phase 3 trials of COMP360 synthetic psilocybin; 26-week durability data held (July 2026).
  • Rolling NDA at the FDA carrying a Priority Review Voucher — a potential launch in first-half 2027.
  • Eli Lilly's $2.8B acquisition of ATAI — Compass's former largest shareholder — leaves CMPS the premier independent name in the category.
  • Our view is unchanged: accumulate on weakness, size it as a clinical-stage biotech.
Featured At (Apr '26) $9.30
Recent High $15.07
Analyst Consensus $24.83
Category Clinical-Stage Biotech
View Full CMPS Coverage

Inside: our buy recommendation, analyst targets, SEC filings, price history & ongoing coverage.

Current Recommendation

SpaceX

NASDAQ: SPCX

Space Launch & Satellite Internet · Newly Public

The largest IPO in history — SpaceX launches ~85% of everything the world puts into orbit and runs Starlink, the only profitable satellite-internet network on Earth. We first wrote up SPCX near $155 as a buy-on-dips, then issued an urgent buy alert near $111 as Wall Street turned bullish; shares have since recovered to ~$146, with the consensus target near $244.

  • Largest IPO ever: ~$75B raised at a ~$1.77T valuation (June 12, 2026).
  • Starlink: $11.4B in 2025 revenue at ~63% margins, 10.3M subscribers across 164 countries.
  • The most-shorted new stock on Wall Street — roughly a third of the float — a coiled short-squeeze setup.
  • A live Tesla–SpaceX merger question: one ticker for the whole Musk empire.
First Call (Jun '26) ~$155
Urgent Buy (Jul '26) ~$111
Recent ~$146
Analyst Consensus ~$244
View Full SPCX Coverage

Inside: our buy recommendation, analyst targets, the short-squeeze setup, catalysts & ongoing coverage.

Past Feature · Sept 2025

Bullish

NYSE: BLSH

Digital Asset Exchange · NYSE IPO

A shorter-term trade — a near-term move we saw in play — flagged at the request of the Grand Cayman investor groups we advise, just after Bullish's NYSE IPO. The report went to just over 20,000 subscribers, and the stock delivered.

  • Featured shortly after the NYSE IPO at approximately $48–53 per share.
  • Shares reached a high of roughly $70 — a ~25–30% move for those who acted on the timing.
  • Open rate 25.46%, click-through 75.9% — among our best-received alerts.
Featured At ~$48–53
High After Feature ~$70
Move ~25–30%
Type Short-Term Trade
Read the Full BLSH Report